Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefiderocol
- Development stage
- Approved
- Lead developer
- Shionogi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Cefiderocol is a novel siderophore cephalosporin antibiotic with a unique mechanism of action that allows it to penetrate the outer membrane of Gram-negative bacteria, including multi-drug resistant strains. It is used to treat complicated urinary tract infections and hospital-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia, caused by susceptible Gram-negative bacteria. Developed by Shionogi & Co., Ltd., it was approved by the FDA in November 2019 and by the EU in April 2020.
- Brand names
- FetrojaFetcroja
- Other names
- 头孢地尔
02
Targets
PBP1A (Penicillin-binding protein 1A)PBP2 (Penicillin-binding protein 2)PBP3 (Peptidoglycan D,D-transpeptidase FtsI)
Beyond the preview
Go deeper on cefiderocol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefiderocol.